Literature DB >> 11368251

Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels.

A K Mantel-Teeuwisse1, J M Kloosterman, A H Maitland-van der Zee, O H Klungel, A J Porsius, A de Boer.   

Abstract

Many drugs besides lipid-lowering drugs affect serum lipid levels in either a potentially harmful or beneficial way, and may therefore increase or decrease the risk of cardiovascular disease. Diuretics, beta-blocking agents, progestogens, combined oral contraceptives containing 'second generation' progestogens, danazol, immunosuppressive agents, protease inhibitors and enzyme-inducing anticonvulsants adversely affect the lipid profile. They increase total cholesterol, low density lipoprotein cholesterol and triglycerides by up to 40, 50 and 300%, respectively, and decrease high density lipoprotein cholesterol by a maximum of 50%. Conversely, alpha-blocking agents, estrogens, hormone replacement therapy, combined oral contraceptives containing 'third generation' progestogens, selective estrogen receptor modulators, growth hormone and valproic acid show mostly beneficial effects on the lipd profile. Some drugs, for example, isotretinoin, acitretin and antipsychotics, mainly elevate triglyceride levels. Adverse or beneficial effects on serum cholesterol levels do not always translate into a higher or lower, respectively, incidence of cardiovascular disease. because these drugs may influence cardiovascular risk through multiple pathways. In some cases, excessive cholesterol levels occur, for example, with protease inhibitor therapy, and several cases of pancreatitis attributable to drug-induced hypertriglyceridaemia have been reported. Some general guidelines on the management of drug-induced dyslipidaemia can be given. Replacement of the dyslipidaemia-inducing drug by an equivalent alternative therapy is preferred. However, such alternatives are often difficult to find. If there is no equivalent alternative and treatment with the dyslipidaemia-inducing drug must be initiated, monitoring of serum lipid levels is important. If drug use is expected to be long term, the existing guidelines for the management of dyslipidaemia in the general population can be applied to drug-induced dyslipidaemia. In cases of extreme hyperlipidaemia, medication use should be reassessed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11368251     DOI: 10.2165/00002018-200124060-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  127 in total

1.  Antihypertensives: much ado about lipids.

Authors:  B A Golomb; M H Criqui
Journal:  Arch Intern Med       Date:  1999-03-22

2.  Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I.

Authors:  V T Miller; R A Muesing; J C LaRosa; D B Stoy; E A Phillips; R J Stillman
Journal:  Obstet Gynecol       Date:  1991-02       Impact factor: 7.661

3.  Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir.

Authors:  M Karmochkine; G Raguin
Journal:  AIDS       Date:  1998-12-24       Impact factor: 4.177

Review 4.  Tamoxifen effects on menopause--associated risk factors and symptoms.

Authors:  A Benshushan; A Brzezinski
Journal:  Obstet Gynecol Surv       Date:  1999-04       Impact factor: 2.347

Review 5.  Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection.

Authors:  W D Simmons; S C Rayhill; H W Sollinger
Journal:  Drug Saf       Date:  1997-08       Impact factor: 5.606

6.  Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors.

Authors:  M Ravid; L Neumann; M Lishner
Journal:  Kidney Int       Date:  1995-03       Impact factor: 10.612

Review 7.  Clinical utility of antilipidemic therapies in chronic renal allograft failure.

Authors:  C Wanner; W Bartens; J Galle
Journal:  Kidney Int Suppl       Date:  1995-12       Impact factor: 10.545

8.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Authors:  A Carr; K Samaras; S Burton; M Law; J Freund; D J Chisholm; D A Cooper
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

Review 9.  Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment. A review paper.

Authors:  T Rosén; G Johannsson; J O Johansson; B A Bengtsson
Journal:  Horm Res       Date:  1995

10.  Association of antihypertensive agents and blood lipids in a population-based survey.

Authors:  D Strickland; J M Sprafka; R V Luepker; R H Grimm
Journal:  Epidemiology       Date:  1994-01       Impact factor: 4.822

View more
  24 in total

Review 1.  Metabolic safety of antihypertensive drugs: myth versus reality.

Authors:  Sameer Stas; Lama Appesh; James Sowers
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

2.  Hypertriglyceridemia: a potential side effect of propofol sedation in critical illness.

Authors:  J-C Devaud; M M Berger; A Pannatier; P Marques-Vidal; L Tappy; N Rodondi; R Chiolero; P Voirol
Journal:  Intensive Care Med       Date:  2012-09-28       Impact factor: 17.440

3.  Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study.

Authors:  Mee Kyoung Kim; Kyungdo Han; Hun-Sung Kim; Yong-Moon Park; Hyuk-Sang Kwon; Kun-Ho Yoon; Seung-Hwan Lee
Journal:  Eur Heart J       Date:  2017-12-21       Impact factor: 29.983

Review 4.  Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder.

Authors:  Antona Wagstaff; Caroline Perry
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

5.  Effect of experimental hyperlipidaemia on the electrocardiographic effects of repeated doses of halofantrine in rats.

Authors:  Jigar P Patel; Dion R Brocks
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 6.  Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.

Authors:  Hua Jin; Jonathan M Meyer; Sunder Mudaliar; Dilip V Jeste
Journal:  Schizophr Res       Date:  2008-01-18       Impact factor: 4.939

7.  Differential postprandial lipoprotein responses in type 2 diabetic men with and without clinical evidence of a former myocardial infarction.

Authors:  Marius Carstensen; Claus Thomsen; Ole Gotzsche; Jens Juul Holst; Jürgen Schrezenmeir; Kjeld Hermansen
Journal:  Rev Diabet Stud       Date:  2005-02-10

Review 8.  Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.

Authors:  Anna Wolska; Richard L Dunbar; Lita A Freeman; Masako Ueda; Marcelo J Amar; Denis O Sviridov; Alan T Remaley
Journal:  Atherosclerosis       Date:  2017-10-20       Impact factor: 5.162

Review 9.  Diuretic-related side effects: development and treatment.

Authors:  Doemnic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-09       Impact factor: 3.738

Review 10.  Drug-induced metabolic syndrome.

Authors:  Marion R Wofford; Deborah S King; T Kristopher Harrell
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-02       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.